Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: Six-month results of the phase 3 COPERNICUS study

Ophthalmology

Volumn 119, Issue 5, 2012, Pages 1024-1032

  Boyer, David ^a   Heier, Jeffrey ^b   Brown, David M ^c   Clark, W Lloyd ^d   Vitti, Robert ^e   Berliner, Alyson J ^e   Groetzbach, Georg ^f   Zeitz, Oliver ^f,g   Sandbrink, Rupert ^f,h   Zhu, Xiaoping ^e   Beckmann, Karola ^f   Haller, Julia A ⁱ  

^a RETINA VITREOUS ASSOCIATES MEDICAL GROUP   (United States)

^b OPHTHALMIC CONSULTANTS OF BOSTON   (United States)

^c HOUSTON METHODIST HOSPITAL   (United States)

^d Palmetto Retina Center   (United States)

^e REGENERON PHARMACEUTICALS INC   (United States)

^f BAYER PHARMA AG   (Germany)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h HEINRICH HEINE UNIVERSITY   (Germany)

ⁱ WILLS EYE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN;

ABSENCE OF SIDE EFFECTS; ARTICLE; CENTRAL RETINA VEIN OCCLUSION; CONTROLLED STUDY; CORNEA ABRASION; CORNEA DISEASE; DISEASE COURSE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; ENDOPHTHALMITIS; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEOVASCULAR GLAUCOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA ARTERY OCCLUSION; RETINA HEMORRHAGE; RETINA MACULA EDEMA; RETINA NEOVASCULARIZATION; RETINA TEAR; RETINA VEIN OCCLUSION; SIDE EFFECT; VISUAL ACUITY; VITREOUS HEMORRHAGE;

AGED; ANGIOGENESIS INHIBITORS; DOUBLE-BLIND METHOD; EYE PAIN; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; PROSPECTIVE STUDIES; QUESTIONNAIRES; RECOMBINANT FUSION PROTEINS; RETINAL VEIN OCCLUSION; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84862779327     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2012.01.042     Document Type: Article

References (20)

1. D.H. Orth, A. Patz Retinal branch vein occlusion Surv Ophthalmol 22 1978 357 376 (Pubitemid 8384633)
2. Branch Vein Occlusion Study Group Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion: a randomized clinical trial Arch Ophthalmol 104 1986 34 41
3. P. Mitchell, W. Smith, A. Chang Prevalence and associations of retinal vein occlusion in Australia: the Blue Mountains Eye Study Arch Ophthalmol 114 1996 1243 1247 (Pubitemid 26338856)
4. R. Klein, S.E. Moss, S.M. Meuer, B.E. Klein The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study Arch Ophthalmol 126 2008 513 518 (Pubitemid 351549845)
5. S.S. Hayreh, M.B. Zimmerman, P. Podhajsky Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics Am J Ophthalmol 117 1994 429 441 (Pubitemid 24115701)
6. S.S. Hayreh Neovascular glaucoma Prog Retin Eye Res 26 2007 470 485 (Pubitemid 47304464)
7. S. Rogers, R.L. McIntosh, N. Cheung International Eye Disease Consortium The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia Ophthalmology 117 2010 313 319
8. Central Vein Occlusion Study Group Natural history and clinical management of central retinal vein occlusion Arch Ophthalmol 115 1997 486 491
9. Central Vein Occlusion Study Group Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion: the Central Vein Occlusion Study Group M report Ophthalmology 102 1995 1425 1433
10. Central Vein Occlusion Study Group A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion: the Central Vein Occlusion Study Group N report Ophthalmology 102 1995 1434 1444
11. D.M. Brown, P.A. Campochiaro, R.P. Singh CRUISE Investigators Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study Ophthalmology 117 2010 1124 1133
12. J.A. Haller, F. Bandello, R. Belfort Jr OZURDEX GENEVA Study Group Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion Ophthalmology 117 2010 1134 1146
13. SCORE Study Research Group A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5 Arch Ophthalmol 127 2009 1101 1114
14. L.P. Aiello, R.L. Avery, P.G. Arrigg Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders N Engl J Med 331 1994 1480 1487 (Pubitemid 24356306)
15. A.N. Economides, L.R. Carpenter, J.S. Rudge Cytokine traps: multi-component, high-affinity blockers of cytokine action Nat Med 9 2003 47 52 (Pubitemid 36098259)
16. J. Holash, S. Davis, N. Papadopoulos VEGF-Trap: a VEGF blocker with potent antitumor effects Proc Natl Acad Sci U S A 99 2002 11393 11398 (Pubitemid 34920936)
17. M.W. Stewart, P.J. Rosenfeld Predicted biological activity of intravitreal VEGF Trap Br J Ophthalmol 92 2008 667 668 (Pubitemid 351684178)
18. J.S. Heier, D. Boyer, Q.D. Nguyen CLEAR-IT 2 Investigators The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor Trap-Eye dosed as-needed after 12-week fixed dosing Ophthalmology 118 2011 1098 1106
19. D.M. Brown, J.S. Heier, T. Ciulla CLEAR-IT 2 Investigators Primary endpoint results of a phase II study of vascular endothelial growth factor Trap-Eye in wet age-related macular degeneration Ophthalmology 118 2011 1089 1097
20. P.A. Campochiaro, G. Hafiz, S.M. Shah Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator Mol Ther 16 2008 791 799 (Pubitemid 351426182)